Komori
Chordia Therapeutics (190A) · InitiativeFirst statedLatest Other Disclosures (2026-06-29): "Advanced"

Pioneering drug discovery research targeting RNA regulatory stress

First written in FY2024. 2 of 4 entries say "Advanced", first in 2026-03-17. Latest entry: 2026-06-29.

4entries
3years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20242024: 120242025: 020252026: 32026
Same theme, other companies
Drug discovery research targeting RNA-regulatory stressA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2024First statedAnnual report

    「Our research and development focuses on RNA regulatory stress, a newly identified cancer stress phenotype. We were among the first to focus on RNA regulatory stress in our research and development activities and, as a leading company in this field, are conducting research and development of new anticancer drugs ahead of the rest of the world.」

    RNA regulatory stress has been identified as a scientific research area spanning multiple pipelines, demonstrating the company's aim to become a leading company in this field.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview It last moved in the Other Disclosures of 2026-06-29: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.